CVKD Cadrenal Therapeutics, Inc.
Financings ·
Cadrenal (Nasdaq: CVKD) received gross proceeds of approximately $3.0 million from one institutional investor. Warrants could add about $5.8 million if exercised in full for cash, the company says.
Cadrenal will sell 207,374 shares at $10.85 plus unregistered warrants for up to 414,748 shares at $10.60, for expected gross proceeds of about $2.2 million. H.C. Wainwright & Co., LLC is exclusive placement agent.
Cadrenal can sell up to $2,169,272 of common stock through H.C. Wainwright & Co., LLC, after it has already sold $7,655,240 under the same agreement. The sales are capped by an SEC rule that applies because its public float is under $75 million.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its lead product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed for heparin-induced thrombocytopenia, an immune-mediated thrombotic disorder. The company acquired CAD-1005 and the CAD-2000 series from Veralox Therapeutics Inc. on December 10, 2025. It completed an End-of-Phase 2 meeting with the FDA on March 26, 2026, which clarified a potential registrational path for a planned Phase 3 pivotal trial, subject to the final FDA meeting minutes and protocol review. CAD-1005 holds an orphan drug designation and FDA Fast Track designation for heparin-induced thrombocytopenia. The broader pipeline includes tecarfarin, an oral vitamin K antagonist designed for chronic use in patients with kidney dysfunction or left ventricular assist devices, and frunexian, a Phase 2-ready intravenous Factor XIa inhibitor for acute care settings. Commencement of the Phase 3 trial will be subject to obtaining sufficient financing.
| Product or program | What it is | Stage |
|---|---|---|
| CAD-1005 | First-in-class selective 12-LOX inhibitor for heparin-induced thrombocytopenia | Phase 2 completed; planned Phase 3 pivotal trial |
| Tecarfarin | Oral vitamin K antagonist for chronic anticoagulation in patients with kidney dysfunction or LVADs | clinical-stage |
| Frunexian | Intravenous Factor XIa inhibitor for acute care hospital settings | Phase 2-ready |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $4.1 million | $4.2 million |
| Net income (loss) | -$13.2 million | -$10.7 million |
| Cash from operations | -$12.6 million | -$7.4 million |
| Cash and equivalents | $4.0 million | $10.0 million |
Our latest story on this, dated Jul 1, 2026: "Cadrenal Therapeutics raises $3.0 million in private placement priced at-the-market". The story links the filing or release it is based on. Read the story.
Cadrenal Therapeutics, Inc. trades under the ticker CVKD on NASDAQ.
Cadrenal Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Cadrenal Therapeutics, Inc. is 1937993. Its filings are on SEC EDGAR.
3,567,592 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Cadrenal Therapeutics, Inc. under United States.
Our directory classifies Cadrenal Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Cadrenal Therapeutics, Inc. is US1276362076.
aibio.space lists Cadrenal Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its lead product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed for heparin-induced thrombocytopenia, an immune-mediated thrombotic disorder.
CAD-1005: First-in-class selective 12-LOX inhibitor for heparin-induced thrombocytopenia Stage: Phase 2 completed; planned Phase 3 pivotal trial.
Tecarfarin: Oral vitamin K antagonist for chronic anticoagulation in patients with kidney dysfunction or LVADs Stage: clinical-stage.
Cadrenal Therapeutics, Inc. reported a net loss of $13.2 million for the fiscal year ended Dec 31, 2025, and used $12.6 million of cash in operations, per its annual report to the SEC.
$4.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a financing. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio